Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs FINGOLIMOD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Off-label: chronic inflammatory demyelinating polyneuropathy (CIDP)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
0.5 mg orally once daily
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Primarily metabolized by CYP4F2 via ω-hydroxylation; minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Also undergoes reversible phosphorylation to active metabolite fingolimod-phosphate.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
38-45%, primarily bound to albumin.
>99.7% bound to human serum albumin; minor binding to lipoproteins.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Vd approximately 1000 L/kg (17,000 L); extensive distribution into tissues, particularly lung, blood cells, and CNS.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is approximately 93% following a single 5 mg dose; food does not significantly affect absorption.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Contraindicated.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
For patients 10 years and older weighing >40 kg: 0.5 mg orally once daily. For patients <10 years or ≤40 kg: Not recommended.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No specific dose adjustment; monitor for bradycardia and atrioventricular block due to age-related conduction system changes. Caution in patients ≥65 years due to limited data.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Risk of serious infections; cases of fatal herpes infections (e.g., varicella zoster) reported. Requires baseline VZV serology and vaccination if negative.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Bradyarrhythmia and AV block (monitor for 6 hours after first dose), increased infection risk (especially herpes viruses), macular edema (ophthalmologic exam at baseline and 3-4 months after initiation), progressive multifocal leukoencephalopathy (PML), posterior reversible encephalopathy syndrome (PRES), severe exacerbation of MS after discontinuation, respiratory effects (decline in FEV1 and DLCO), liver injury, fetal risk, blood pressure effects (hypertension), and risk of basal cell carcinoma.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Patients with recent myocardial infarction (within 6 months), unstable angina, stroke, transient ischemic attack, decompensated heart failure, or history of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome (unless pacemaker in place), severe active infections, and hypersensitivity to fingolimod or any of its excipients.
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Grapefruit juice and Seville oranges may increase drug levels; avoid consumption.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular septal defects, particularly during the first trimester. Human data are limited, but case reports suggest potential fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Fingolimod is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 2:1. Based on a typical maternal dose, the estimated infant exposure is about 0.2-0.4% of the maternal weight-adjusted dose. Due to potential for serious adverse effects (immunosuppression, bradycardia), breastfeeding is not recommended during fingolimod therapy.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dose adjustment guidelines exist for fingolimod during pregnancy due to teratogenicity. Pregnancy is a contraindication; discontinue fingolimod before conception or as soon as pregnancy is detected. Pharmacokinetic studies in pregnancy are lacking; no evidence of altered metabolism requiring dose adjustment if used inadvertently.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
First-dose monitoring required for 6 hours due to bradycardia risk; obtain baseline ECG, CBC, LFTs. Avoid live vaccines; screen for latent infections. Rebound disease activity may occur upon discontinuation; taper not needed but monitor closely.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Your heart rate will be monitored for 6 hours after your first dose.,Do not stop fingolimod without consulting your doctor; stopping can cause severe return of MS symptoms.,Avoid grapefruit juice and Seville oranges.,Report any signs of infection, slow heart rate, or visual changes immediately.,Use effective contraception during treatment and for 2 months after stopping.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs FINGOLIMOD, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. FINGOLIMOD is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and FINGOLIMOD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of FINGOLIMOD is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and FINGOLIMOD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. FINGOLIMOD is classified as Category C. FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular sept. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.